The civic record
Read. Follow. Verify.Lobbying Report: 340B Health (Q2 2026)
Record date · July 20, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This document is a quarterly lobbying disclosure filed by 340B Health, an organization representing hospitals that participate in the federal 340B drug pricing program. It details the specific federal legislation, proposed rules, and agency actions the group monitored or influenced during the second quarter of 2026.
This report identifies the specific federal bills and regulatory actions that 340B Health is actively lobbying on, which may influence future changes to drug pricing policies and hospital reporting requirements.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
340B Health
The organization is the registrant and client, responsible for reporting its lobbying activities and expenditures.
Hospitals participating in the 340B program
These entities are represented by 340B Health and are subject to the legislative and regulatory changes monitored by the organization.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What is 340B Health?
How much did 340B Health spend on lobbying this quarter?
What specific issues were they focused on?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceLobbying Activity
The Cleveland Clinic Foundation
on behalf of Cleveland Clinic Foundation
2026
“Quantum computing Immigration Issues National Institute of Health CHILDReN Act EARLY Minds Act Interoperability Issues Brain Health 340B Graduate Medical Education Workforce Issues Payer Accountability Organ Transplant Legislation Healthy Competition Act Price Transparency ”
340B Health
2026
“The SECURE 340B Act (H.R. 9599); The Tax-Exempt Hospital Transparency Act (H.R.9504); 340B PATIENTS Act (H.R. 4581/S.2372); Community Health Center Drug Pricing Protection Act (H.R. 7391); 2027 OPPS Proposed Rule; Information Collection Request Title: 340B Rebate Model Pilot Program Application, Implementation, and Evaluation, OMB Number 0906-NEW; Manufacturer Demand for Access to in-House Pharmacy Claims Data; Lilly 340B Drug Pricing Denial; HRSA Rebate Model Pilot pending regulation; Pending Senate "Gang of Six" draft 340B legislation; FY27 Appropriations legislation; Pending introduction of updated and expanded Community Health Center Drug Pricing Protection Act.”
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Focus on Rebate Model Pilot
The organization is heavily focused on the HRSA Rebate Model Pilot, indicating a significant shift in regulatory oversight for 340B drug pricing.
Connected Entities
Sources
lda.gov
Analysis Score
0–100- Significance60How much this matters to a regular citizen
- Controversy40Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools